Resistance mechanisms underlying the EGFR-targeted therapies in glioblastoma / 国际药学研究杂志

Glioblastoma multiforme (GBM) is the most common primary malignant neoplasm of the central nervous system in adults. Previous work has shown that the over- expression of epidermal growth factor receptor (EGFR) and EGFR gene amplification was found in approximately 40- 60% of GBM patients, of which about 40% with EGFR mutations. Presently, multiple therapeutic drugs targeting EGFR have been used in clinical trials. However EGFR targeted therapy has limited efficacy in patients with GBM. It remains a haunting challenge to overcome the primary and secondary drug resistance to EGFR-targeted therapy in GBM patients. This review summarizes recent advances in the main resistance mechanisms underlying the EGFR-targeted therapies in glioblastoma.